CoChat

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Background: The affliction of allergic rhinitis (AR) has been trivialised in the past. Recent initiatives by the European Academy of Allergy & Clinical Immunology and by the EU parliament seek to rectify that situation. The aim of this study was to provide a comprehensive picture of the burden and unmet need of AR patients. Methods: This was a cross‐sectional, online, questionnaire‐based study (June–July 2011) including symptomatic seasonal AR (SAR) patients (≥18 years) from a panel. SAR episode pattern, severity, medication/co‐medication usage, residual symptoms on treatment, number of healthcare visits, absenteeism and presenteeism were collected. Results: One thousand patients were recruited (mild: n = 254; moderate/severe: n = 746). Patients with moderate/severe disease had significantly more symptomatic episodes/year (8.0 vs 6.0/year; p = 0.025) with longer episode‐duration (12.5 vs 9.8 days; p = 0.0041) and more commonly used ≥2 AR therapies (70.5 vs 56.1 %; OR 1.87; p = 0.0001), looking for better and faster nasal and ocular symptom relief. The reported symptom burden was high irrespective of treatment, and significantly (p < 0.0001) higher in the moderate/severe group. Patients with moderate/severe AR were more likely to visit their GP (1.61 vs 1.19 times/year; OR: 1.49; p = 0.0061); due to dissatisfaction with therapy in 35.4 % of cases. Patients reported SAR‐related absenteeism from work on 4.1 days/year (total cost to UK: £1.25 billion/year) and noted presenteeism for a mean of 37.7 days/year (vs 21.0 days/year; OR 1.71; p = 0.0048). Asthma co‐morbid patients reported the need to increase their reliever‐ (1 in 2 patients) and controller‐medication (1 in 5 patients) if they did not take their rhinitis medication. Conclusions: This study differentiated between patients with mild and moderate/severe AR, demonstrating a burden of poorly controlled symptoms and high co‐medication use. The deficiency in obtaining symptom control with what are currently considered firstline treatments suggests the need for a novel therapeutic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13601-015-0083-6

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Nasal and ocular symptom burden reported by seasonal allergic rhinitis patients with mild (n = 254) or moderate/severe disease (n = 746) on the day of assessment. Over 90 % of these patients in both groups were taking AR medication (see Table 2). Data are presented as mean and standard deviation. rTNSS: reflective total nasal symptom score (max = 12); rTOSS: reflective total ocular symptom score (max = 9). *p < 0.0001 vs mild AR
Fig. 1 Nasal and ocular symptom burden reported by seasonal allergic rhinitis patients with mild (n = 254) or moderate/severe disease (n = 746) on the day of assessment. Over 90 % of these patients in both groups were taking AR medication (see Table 2). Data are presented as mean and standard deviation. rTNSS: reflective total nasal symptom score (max = 12); rTOSS: reflective total ocular symptom score (max = 9). *p < 0.0001 vs mild ARCC BY · PubMed Central
Fig. 2 Proportion of patients with mild (n = 254) or moderate severe AR (n = 746) scoring a ‘2’ (moderate) or ‘3’ (severe) for individual nasal and ocular symptom scores on the day of assessment. Over 90 % of these patients in both groups were taking AR medication (see Table 2). Significance values for mild vs moderate/severe groups are given for each level of symptom severity in Table 3
Fig. 2 Proportion of patients with mild (n = 254) or moderate severe AR (n = 746) scoring a ‘2’ (moderate) or ‘3’ (severe) for individual nasal and ocular symptom scores on the day of assessment. Over 90 % of these patients in both groups were taking AR medication (see Table 2). Significance values for mild vs moderate/severe groups are given for each level of symptom severity in Table 3CC BY · PubMed Central
Fig. 3 Presenteeism due to SAR reported by patients with mild disease (n = 164) and those with moderate/severe disease (n = 521). *p ≤ 0.0093 vs mild AR. Patients with moderate/severe AR significantly (OR 3.52; CI 2.10–6.13; p < 0.0001) more likely than those with mild AR to have a >50 % impairment in their work productivity due to their SAR symptoms
Fig. 3 Presenteeism due to SAR reported by patients with mild disease (n = 164) and those with moderate/severe disease (n = 521). *p ≤ 0.0093 vs mild AR. Patients with moderate/severe AR significantly (OR 3.52; CI 2.10–6.13; p < 0.0001) more likely than those with mild AR to have a >50 % impairment in their work productivity due to their SAR symptomsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 105

Metadata

Authors
Price, D., Scadding, G., Ryan, D., Bachert, C., Canonica, G. W., Mullol, J., Klimek, L., Pitman, R., Acaster, S., Murray, R., & Bousquet, J.
Affiliations
  • University of Aberdeen (GB)
  • Royal National Throat Nose and Ear Hospital (GB)
  • University of Edinburgh (GB)
  • Ghent University Hospital (BE)
  • Ospedale Policlinico San Martino (IT)
  • Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
  • Zentrum für Rhinologie und Allergologie (DE)
  • ICON Oxford UK
  • Acaster Consulting London UK
  • Medscript Ltd Dundalk Ireland
  • Inserm (FR)
Corresponding author
Price, David
Venue
Clinical and Translational Allergy
Publisher
Wiley
Published
2015-01
Volume
5
Issue
1
Pages
39-39
ISSN
2045-7022 (ISSN-L)
OpenAlex
W2174402243
Cited by
105
References
47
Citations by year
2026: 1 · 2025: 5 · 2024: 3 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 19 · 2019: 18 · 2018: 15 · 2017: 13 · 2016: 9
FWCI
10.81
Type
journal article
Language
en
Open access
Locations
  • Clinical and Translational Allergy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
  • HAL (submittedVersion, cc-by)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Keywords
allergic rhinitis, disease burden, health care utilization, absenteeism, presenteeism, symptom severity, asthma comorbidity, concomitant medications, unmet needs, symptom management, health care costs, UK adults, second-line therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. https://app.cochat.ai/papers/10.1186/s13601-015-0083-6
The paper
Price, D., Scadding, G., Ryan, D., Bachert, C., Canonica, G. W., Mullol, J., Klimek, L., Pitman, R., Acaster, S., Murray, R., & Bousquet, J. (2015). The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey. Clinical and Translational Allergy. https://doi.org/10.1186/s13601-015-0083-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.